Core Insights - MSCI announced the inclusion of JingTai Technology (02228) in the MSCI China Index, effective after the market close on November 24, 2025, recognizing its innovation in AI and robotics for new drug and material development [1][4]. Group 1: MSCI Inclusion - The MSCI China Index added 26 stocks, including JingTai Technology, which signifies entry into the MSCI global standard index series, attracting passive investment funds [3][4]. - The selection for the MSCI China Index is based on objective quantitative metrics such as market capitalization, free float, liquidity, and market investability, indicating JingTai Technology meets strict international standards [4]. Group 2: Company Overview - JingTai Technology is an innovative R&D platform integrating quantum physics, AI, and standardized experimental robotics, focusing on the commercialization of AI in various sectors including pharmaceuticals, energy, agriculture, and new materials [5]. - The company has established partnerships with over 300 international enterprises and research institutions, and aims to achieve profitability in the first half of 2025 [5]. - JingTai Technology is one of the few platforms with high-value collaborations in both AI small molecule and AI biopharmaceutical development, serving 15 of the top 20 global pharmaceutical companies [5].
晶泰科技(02228)获纳入MSCI中国指数，全球投资基准认可发展潜力